Biotechnology - Techseriesinsight

January 29, 2026
PRNewswire
Biotechnology, News

LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress

The venture capital arm of the medical research organisation, LifeArc, had its most active year to date in 2025, announcing investments in four new innovative life sciences portfolio companies...

January 28, 2026
Business Wire
Biotechnology, News

Premier Radiology Services Acquires NRAD, Further Expanding Teleradiology Capabilities

Premier Radiology Services (Premier) is pleased to announce the acquisition of National Radiology Solutions (NRAD), a highly regarded teleradiology provider recognized for its diverse team of specialists and deep...

January 28, 2026
PRNewswire
Biotechnology, News

Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers

A global provider of life science tools, reagents, and diagnostic products, today announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform. Early detection of neurodegenerative...

January 27, 2026
Business Wire
Biotechnology, News

Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board

The appointment of Steve Kelsey, MD, as independent director to its Advisory Board. Dr. Kelsey, currently President, Research and Development at Revolution Medicines, brings more than two decades of...

January 27, 2026
PRNewswire
Biotechnology, News

Libevitug Approved in China as First-in-Class Hepatitis D Treatment

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with...

January 23, 2026
Business Wire
Biotechnology, News

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

A commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a chemotherapy-free combination...

January 22, 2026
Business Wire
Biotechnology, News

Vizient State of the Industry Report: Healthcare Faces a Reset in 2026 and Beyond

Foundational pressures — including affordability concerns, workforce shortages, capacity constraints and shifting payer dynamics — are intensifying, according to the report. In response, many healthcare organizations are demonstrating resilience,...

January 21, 2026
Business Wire
Biotechnology, News

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

A global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay (tfMRD) in colorectal...

January 20, 2026
Business Wire
Biotechnology, News

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives,...

January 20, 2026
Business Wire
Biotechnology, News

Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research

A specialized oncology CRO, known for its expertise in early phase oncology trials and a strong biometrics and Functional Service Provider (FSP) model. Following the close of the transaction,...